|
1
|
American Cancer Society, . Facts &
Figures. American Cancer Society Inc. Atlanta, GA: 2017.
|
|
2
|
Sørlie T, Perou CM, Tibshirany R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dinh P, Satirou C and Piccart MJ: The
evaluation of treatment strategies: Aiming at the target. Breast.
16 (Suppl 2):S10–S16. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anders CK, Winer EP, Ford JM, Dent R,
Silver DP, Siedge GW and Carey LA: Poly(ADP-ribose) polymerase
inhibition: ‘Targeted’ therapy for triple-negative breast cancer.
Clin Cancer Res. 16:4702–4710. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tindle HA, Davis RB, Phillips RS and
Eisenburg DM: Trends in the use of complementary and alternative
medicine by US adults: 1997–2002. Altern Ther Health Med. 11:42–49.
2005.PubMed/NCBI
|
|
8
|
Molassiotis A, Scott JA, Kearney N, Pud D,
Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V,
Margulies A, et al: Complementary and alternative medicine use in
breast cancer patients in Europe. Support Care Cancer. 14:260–267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Helyer LK, Chin S, Chui BK, Fitzgerald B,
Verma S, Rakovitch E, Dranitsaris G and Clemons M: The use of
complementary and alternative medicines among patients with locally
advanced breast cancer - a descriptive study. BMC Cancer. 6:39–46.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mukherjee B, Telang N and Wong GY: Growth
inhibition of estrogen receptor positive human breast cancer cells
by Taheebo from the inner bark of Tabebuia avellanedae tree.
Int J Mol Med. 24:253–260. 2009.PubMed/NCBI
|
|
11
|
Li G, Sepkovic DW, Bradlow HL, Telang NT
and Wong GY: Lycium barbarum inhibits growth of estrogen
receptor positive human breast cancer cells by favorably altering
estradiol metabolism. Nutr Cancer. 61:408–414. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Telang NT, Li G, Sepkovic DW, Bradlow HL
and Wong GY: Anti-proliferative effects of Chinese herb Cornus
officinalis in a cell culture model for estrogen
receptor-positive clinical breast cancer. Mol Med Rep. 5:22–28.
2012.PubMed/NCBI
|
|
13
|
Telang N, Li G, Sepkovic D, Bradlow HL and
Wong GY: Comparative efficacy of extracts from Lycium
barbarum bark and fruit on estrogen receptor positive human
mammary carcinoma MCF-7 cells. Nutr Cancer. 66:278–284. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Telang N, Li G, Katdare M, Sepkovic D,
Bradlow L and Wong G: Inhibitory effects of Chinese nutritional
herbs in isogenic breast carcinoma cells with modulated estrogen
receptor function. Oncol Lett. 12:3949–3957. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Telang NT, Nair HB and Wong GY: Efficacy
of Tabebuia avellanedae extract on a cell culture model for
triple negative breast cancer. Cancer Res. 74 Suppl:SABCS,
P5-14-02. 2014.
|
|
16
|
Telang N, Nair HB and Wong GY: Effect of
Cornus officinalis (CO) on a model for triple negative
breast cancer. Cancer Res. 75 Suppl:SABCS, P3-09-04. 2015.
|
|
17
|
Telang N, Nair HB and Wong GY: Efficacy of
Dipsacus asperoides (DA) in a model for triple negative
breast cancer. Cancer Res. 77 (Suppl 4):P4-13-04-P4-13-04. 2017.
View Article : Google Scholar
|
|
18
|
Seeram NP, Schutzki R, Chandra A and Nair
MG: Characterization, quantification, and bioactivities of
anthocyanins in Cornus species. J Agric Food Chem.
50:2519–2523. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang JS, Chiang LC, Hsu FF and Lin CC:
Chemoprevention against hepatocellular carcinoma by Cornus
officinalis in vitro. Am J Chin Med. 32:717–725. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neve RM, Chin K, Fridlyand J, Yeh J,
Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A
collection of breast cancer cell lines for the study of
functionally distinct cancer subtypes. Cancer Cell. 10:515–527.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Subik K, Lee JF, Baxter L, Strzepak T,
Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and
Tang P: The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67
and AR by immunohistochemical analysis in breast cancer cell lines.
Breast Cancer (Auckl). 4:35–41. 2010.PubMed/NCBI
|
|
22
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16 (Suppl
1):S1–S11. 2011. View Article : Google Scholar
|
|
23
|
Lin NU, Vanderplas A, Hughes ME, Theriault
RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP and Weeks JC:
Clinicopathologic features, patterns of recurrence, and survival
among women with triple-negative breast cancer in the National
Comprehensive Cancer Network. Cancer. 118:5463–5472. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Telang N: Putative cancer-initiating stem
cells in cell culture models for molecular subtypes of clinical
breast cancer. Oncol Lett. 10:3840–3846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cox LA, Chen G and Lee EY: Tumor
suppressor genes and their role in breast cancer. Breast Cancer Res
Treat. 32:19–38. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burkhart DL and Sage J: Cellular
mechanisms of tumor suppression by the retinoblastoma gene. Nat Rev
Cancer. 8:671–682. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bosco EE and Knudson ES: RB in breast
cancer: At the crossroads of tumorigenesis and treatment. Cell
Cycle. 6:667–671. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Musgrove EA, Caldon CE, Barraclough J,
Stone A and Sutherland RL: Cyclin D as a therapeutic target in
cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alves CL, Elias D, Lyng M, Bak M,
Kirkegaard T, Lykkesfeldt AE and Ditzel HJ: High CDK6 protects
cells from fulvestrant-mediated apoptosis and is a predictor of
resistance to fulvestrant in estrogen receptor-positive metastatic
breast cancer. Clin Cancer Res. 22:5514–5526. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
VanArsdale T, Boshoff C, Arndt KT and
Abraham RT: Molecular pathways: Targeting the cyclin D-CDK4/6 axis
for cancer treatment. Clin Cancer Res. 21:2905–2910. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Foidart P, Yip C, Radermacher J, Blacher
S, Lienard M, Montero-Ruiz L, Maquoi E, Montaudon E,
Château-Joubert S, Collignon J, et al: Expression of MT4-MMP, EGFR,
and RB in triple-negative breast cancer strongly sensitizes tumors
to erlotinib and palbociclib combination therapy. Clin Cancer Res.
Nov 30–2018.(Epub ahead of print). doi:
10.1158/1078–0432.CCR-18-1880.
|
|
33
|
Tait SW and Green DR: Mitochondrion and
cell death: Outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ichim G and Tait SW: A fate worse than
death: Apoptosis as an oncogenic process. Nat Rev Cancer.
16:539–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
